drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy (anti-CD20 monoclonal antibody)
drug_description
Chimeric anti-CD20 monoclonal antibody (brand: MabThera) given IV (1 g on days 0 and 15) to deplete CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing autoantibody/immune-complex formation, antigen presentation, and B-cell–derived cytokines in refractory chronic hypersensitivity pneumonitis.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing B cell–mediated autoantibody production, immune complex formation, antigen presentation, and cytokine release.
drug_name
Rituximab
nct_id_drug_ref
NCT07035561